MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrenceRadhika Mathur, J Costello, Yalan Zhang et al.|Neuro-Oncology|2020Cited by 96
Prospective genomically guided identification of “early/evolving” and “undersampled” IDH-wildtype glioblastoma leads to improved clinical outcomesYalan Zhang, David A. Solomon, Soonmee Cha et al.|Neuro-Oncology|2022Cited by 31
Optimal tumor sampling for immunostaining of biomarkers in breast carcinomaJuliana Tolles, Annette M. Molinaro|Breast Cancer Research|2011Cited by 25
Relationship of In Vivo MR Parameters to Histopathological and Molecular Characteristics of Newly Diagnosed, Nonenhancing Lower-Grade GliomasTracy Luks, Sarah J. Nelson, Llewellyn E. Jalbert et al.|Translational Oncology|2018Cited by 8
HGG-32. PNOC008: A PILOT TRIAL TESTING THE CLINICAL BENEFIT OF USING MOLECULAR PROFILING TO DETERMINE AN INDIVIDUALIZED TREATMENT PLAN IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMA (EXCLUDING DIFFUSE INTRINSIC PONTINE GLIOMA)Andrea Franson, Sabine Mueller, Lindsay Kilburn et al.|Neuro-Oncology|2024Cited by 2